Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
Immunofluorescent analysis of HER-2/ErbB2 (green) showing membrane staining in SK-BR-3 cells (right) compared to a negative control without primary antibody (left). Cells were was permeabilized with 0.1% Triton X-100 in TBS for 5-10 minutes and blocked with 3% BSA-PBS for 30 minutes at room temperature. Cells were probed with a HER-2/ErbB2 monoclonal antibody (Product # MA5-13675) in 3% BSA-PBS at a dilution of 1:100 and incubated overnight at 4°C in a humidified chamber. Cells were washed with PBST and incubated with a DyLight-488 conjugated secondary antibody in PBS at room temperature in the dark. Nuclei were stained with DAPI (blue) and images were taken at a magnification of 60x.
|Tested species reactivity||Human, Mouse, Primate, Rat|
|Published species reactivity||Avian, Rat, Hamster, Cat, Human, Mouse, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||A synthetic peptide from the C-terminus of human c-erbB-2 protein. This Sequence Is Identical In Rat Neu Protein.|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:10-1:100|
|Immunoprecipitation (IP)||2µg/mg protein lysate|
|Western Blot (WB)||0.5-1.0 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-13675 targets HER-2 in IHC, IP, ICC, IF, FACS and WB applications and shows reactivity with Human, mouse, Non-human primate, and Rat samples.
The MA5-13675 immunogen is a synthetic peptide from the C-terminus of human c-erbB-2 protein. This Sequence Is Identical In Rat Neu Protein.
This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
IP-MS enrichment of ERBB2 (LFQ intensity): ERBB2 was enriched 205-fold from HCT116 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and ERBB2 antibody (Part No. MA5-13675). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.
MA5-13675 was used in immunohistochemistry to determine the best method to assess HER2 status in breast cancer samples
|Yardley DA,Kaufman PA,Huang W,Krekow L,Savin M,Lawler WE,Zrada S,Starr A,Einhorn H,Schwartzberg LS,Adams JW,Lie Y,Paquet AC,Sperinde J,Haddad M,Anderson S,Brigino M,Pesano R,Bates MP,Weidler J,Bosserman L||Breast cancer research : BCR (17:null)||2015|
HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
MA5-13675 was used in immunohistochemistry to review the literature on HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma
|Hechtman JF,Polydorides AD||Archives of pathology & laboratory medicine (136:691)||2012|
Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome.
MA5-13675 was used in immunohistochemistry to study the prognostic value of stromal caveolin-1 in breast cancer
|El-Gendi SM,Mostafa MF,El-Gendi AM||Pathology oncology research : POR (18:459)||2012|
Clinicopathologic features of the mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation in a subset of six cases.
MA5-13675 was used in immunohistochemistry to study six cases of mixed epithelial and mesenchymal type metaplastic breast carcinoma with myoepithelial differentiation
|Yigit S,Pehlivan FS,Evcim G,Etit D||Pathology, research and practice (208:147)||2012|
Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression.
MA5-13675 was used in immunohistochemistry to identify biomarkers that predict the recurrence of benign meningiomas
|Abdelzaher E,El-Gendi SM,Yehya A,Gowil AG||British journal of neurosurgery (25:707)||2011|
Detection of minimal residual disease in blood and bone marrow in early stage breast cancer.
MA5-13675 was used in immunohistochemistry to study the presence of circulating tumor cells in blood and disseminated tumor cells in bone marrow of women with early stage breast cancer
|Krishnamurthy S,Cristofanilli M,Singh B,Reuben J,Gao H,Cohen EN,Andreopoulou E,Hall CS,Lodhi A,Jackson S,Lucci A||Cancer (116:3330)||2010|
Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.
MA5-13675 was used in immunohistochemistry to study the therapeutic potential of HER-2/neu vaccination plus low doses of GM-CSF and IL-2 in metastatic breast carcinoma
|Norell H,Poschke I,Charo J,Wei WZ,Erskine C,Piechocki MP,Knutson KL,Bergh J,Lidbrink E,Kiessling R||Journal of translational medicine (8:null)||2010|
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
MA5-13675 was used in immunohistochemistry to study the HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats
|Misirlioglu D,Nak D,Ozyigit MO,Nak Y,Akkoc A||Journal of feline medicine and surgery (11:885)||2009|
Ovarian adenocarcinomas in the laying hen and women share similar alterations in p53, ras, and HER-2/neu.
MA5-13675 was used in immunohistochemistry to investigate the similar changes of p53, ras, and HER-2/neu genes in ovatian adenocarcinomas between chicken and human
|Hakim AA,Barry CP,Barnes HJ,Anderson KE,Petitte J,Whitaker R,Lancaster JM,Wenham RM,Carver DK,Turbov J,Berchuck A,Kopelovich L,Rodriguez GC||Cancer prevention research (Philadelphia, Pa.) (2:114)||2009|
Loss of annexin A1 expression in breast cancer progression.
MA5-13675 was used in immunohistochemistry to study ANXA1 expression during the progression of breast carcinomas
|Cao Y,Li Y,Edelweiss M,Arun B,Rosen D,Resetkova E,Wu Y,Liu J,Sahin A,Albarracin CT||Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry (16:530)||2008|
Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas.
MA5-13675 was used in immunohistochemistry to study triple negative breast carcinoma histopathology and gene expression patterns in order to define clinically significant sub-groups
|Kreike B,van Kouwenhove M,Horlings H,Weigelt B,Peterse H,Bartelink H,van de Vijver MJ||Breast cancer research : BCR (9:null)||2008|
Primary neuroendocrine carcinoma of the breast: a case report.
MA5-13675 was used in immunohistochemistry to report on a case of primary neuroendocrine carcinoma of the breast
|Yaren A,Kelten C,Akbulut M,Teke Z,Duzcan E,Erdem E||Tumori (93:496)||2007|
Abundance and localization of skeletal muscle-related erbB2 may stimulate tumour growth during initial stages of oral oncogenesis.
MA5-13675 was used in immunohistochemistry to study the role of skeletal muscle-related erbB2 in stimulating tumor growth in oral oncogenesis
|Vairaktaris E,Moulavassili P,Loukeri S,Spyridonidou S,Yapijakis C,Vassiliou S,Nkenke E,Vylliotis A,Papakosta V,Lazaris A,Patsouris E||Journal of musculoskeletal & neuronal interactions (7:185)||2007|
Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
MA5-13675 was used in immunohistochemistry to study the value of serum HER-2 receptor extracellular domain measurements for predicting the response to chemotherapy in primary breast cancer patients
|Mazouni C,Hall A,Broglio K,Fritsche H,Andre F,Esteva FJ,Hortobagyi GN,Buzdar AU,Pusztai L,Cristofanilli M||Cancer (109:496)||2007|
[An analysis of genetic transmission in a father and son with osteosarcoma].
MA5-13675 was used in immunohistochemistry to report on a case of a father and son with familial osteosarcoma
|Tokatli F,Alas RC,Altaner S,Pala F,Uygun K,Uzal C,Yalniz E||Acta orthopaedica et traumatologica turcica (40:407)||2007|
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
MA5-13675 was used in immunohistochemistry to study breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation
|Schmidt MK,Tollenaar RA,de Kemp SR,Broeks A,Cornelisse CJ,Smit VT,Peterse JL,van Leeuwen FE,Van't Veer LJ||Journal of clinical oncology : official journal of the American Society of Clinical Oncology (25:64)||2007|
Effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells: implications for breast cancer biology.
MA5-13675 was used in immunohistochemistry to study the effect of c-neu/ ErbB2 expression levels on estrogen receptor alpha-dependent proliferation in mammary epithelial cells
|Shyamala G,Chou YC,Cardiff RD,Vargis E||Cancer research (66:10391)||2006|
Clonal nature of sclerosing polycystic adenosis of salivary glands demonstrated by using the polymorphism of the human androgen receptor (HUMARA) locus as a marker.
MA5-13675 was used in immunohistochemistry to investigate clonality of sclerosing polycystic adenosis by human androgen receptor polymorphism
|Skálová A,Gnepp DR,Simpson RH,Lewis JE,Janssen D,Sima R,Vanecek T,Di Palma S,Michal M||The American journal of surgical pathology (30:939)||2006|
MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC).
MA5-13675 was used in immunohistochemistry to study the expression of MUC4 in different stages of non-small cell lung cancer and its relationship with ErbB2 expression
|Karg A,Dinç ZA,Başok O,Uçvet A||Pathology, research and practice (202:577)||2006|
Non-invasive (intracapsular) carcinoma ex pleomorphic adenoma: recognition of focal carcinoma by HER-2/neu and MIB1 immunohistochemistry.
MA5-13675 was used in immunohistochemistry to characterize non-invasive carcinoma ex pleomorphic adenoma through HER-2/neu and MIB1 expression
|Di Palma S,Skálová A,Vanìèek T,Simpson RH,Stárek I,Leivo I||Histopathology (46:144)||2005|
Cystic hypersecretory carcinoma: rare and poorly recognized variant of intraductal carcinoma of the breast. Report of five cases.
MA5-13675 was used in immunohistochemistry to report the clinical cases of cystic hypersecretory carcinoma
|Skalova A,Ryska A,Kajo K,Di Palma S,Kinkor Z,Michal M||Histopathology (46:43)||2005|
Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
MA5-13675 was used in immunohistochemistry to study the effect of vitamin D receptor gene dosage on mammary gland morphology and tumorigenesis
|Zinser GM,Welsh J||Carcinogenesis (25:2361)||2004|
Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.
MA5-13675 was used in immunohistochemistry to study the histopathology and immunohistochemistry of breast carcinoma in pregnant women
|Middleton LP,Amin M,Gwyn K,Theriault R,Sahin A||Cancer (98:1055)||2003|
Mucin-rich variant of salivary duct carcinoma: a clinicopathologic and immunohistochemical study of four cases.
MA5-13675 was used in immunohistochemistry to study the clinicopathology and immunohistochemistry of four cases of mucin-rich variant of salivary duct carcinoma
|Simpson RH,Prasad AR,Lewis JE,Skálová A,David L||The American journal of surgical pathology (27:1070)||2003|
Her2/neu overexpression in differentiated thyroid carcinomas predicts metastatic disease.
MA5-13675 was used in immunohistochemistry to study the prognostic value of Her2/neu overexpression in differentiated thyroid carcinomas
|Kremser R,Obrist P,Spizzo G,Erler H,Kendler D,Kemmler G,Mikuz G,Ensinger C||Virchows Archiv : an international journal of pathology (442:322)||2003|
Automated quantification of apoptosis after neoadjuvant chemotherapy for breast cancer: early assessment predicts clinical response.
MA5-13675 was used in immunohistochemistry to study whether early assessment of apoptosis following breast cancer neoadjuvant chemotherapy predicts clinical response
|Davis DW,Buchholz TA,Hess KR,Sahin AA,Valero V,McConkey DJ||Clinical cancer research : an official journal of the American Association for Cancer Research (9:955)||2003|
Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
MA5-13675 was used in immunohistochemistry to study whether refining the grading of low-grade neuroendocrine tumors of the midgut and unknown origin is of prognostic/predictive value
|Van Eeden S,Quaedvlieg PF,Taal BG,Offerhaus GJ,Lamers CB,Van Velthuysen ML||Human pathology (33:1126)||2002|
Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ.
MA5-13675 was used in immunohistochemistry to study the expression of COX-2 in human breast cancers and adjacent ductal carcinoma in situ
|Half E,Tang XM,Gwyn K,Sahin A,Wathen K,Sinicrope FA||Cancer research (62:1676)||2002|
Impedance spectroscopy assisted by magnetic nanoparticles as a potential biosensor principle for breast cancer cells in suspension.
MA5-13675 was used in ELISA to study the use of impedence spectroscopy combined with magnetic nanoparticles for the measurement of beast cancer cells in suspension
|Silva JG,Cárdenas RA,Quiróz AR,Sánchez V,Lozano LM,Pérez NM,López J,Villanueva C,González CA||Physiological measurement (35:931)||2014|
|Not Applicable||Not Cited||
Comparison of central HER2 testing with quantitative total HER2 expression and HER2 homodimer measurements using a novel proximity-based assay.
MA5-13675 was used in ELISA to develop and evaluate a novel proximity-based assay for quantitating total HER2 expression and HER2 homodimer
|Huang W,Reinholz M,Weidler J,Yolanda L,Paquet A,Whitcomb J,Lingle W,Jenkins RB,Chen B,Larson JS,Tan Y,Sherwood T,Bates M,Perez EA||American journal of clinical pathology (134:303)||2010|
Profiling receptor tyrosine kinase activation by using Ab microarrays.
MA5-13675 was used in ELISA to study the receptor tyrosine kinase activation by through antibody microarrays
|Nielsen UB,Cardone MH,Sinskey AJ,MacBeath G,Sorger PK||Proceedings of the National Academy of Sciences of the United States of America (100:9330)||2003|
Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.
MA5-13675 was used in western blot to study the pharmacodynamics of afatinib in HER2-positive gastric cancer using PET
|Janjigian YY,Viola-Villegas N,Holland JP,Divilov V,Carlin SD,Gomes-DaGama EM,Chiosis G,Carbonetti G,de Stanchina E,Lewis JS||Journal of nuclear medicine : official publication, Society of Nuclear Medicine (54:936)||2013|
A cell-based screening system for influenza A viral RNA transcription/replication inhibitors.
MA5-13675 was used in western blot to develop a cell-based screening system to identify compounds that inhibit influenza A viral RNA transcription/replication
|Ozawa M,Shimojima M,Goto H,Watanabe S,Hatta Y,Kiso M,Furuta Y,Horimoto T,Peters NR,Hoffmann FM,Kawaoka Y||Scientific reports (3:null)||2013|
Protective effects of prepubertal genistein exposure on mammary tumorigenesis are dependent on BRCA1 expression.
MA5-13675 was used in western blot to study the role of BRCA-1 in the protective effects of prepubertal genistein against mammary tumorigenesis
|de Assis S,Warri A,Benitez C,Helferich W,Hilakivi-Clarke L||Cancer prevention research (Philadelphia, Pa.) (4:1436)||2011|
Protein expression profiling of primary mammary epithelial cells derived from MMTV-neu mice revealed that HER2/NEU-driven changes in protein expression are functionally clustered.
MA5-13675 was used in western blot to profile protein expression in primary mammary epithelial cells derived from MMTV-neu mice to identify novel biomarkers of tumorigenesis
|Park S,Lee KM,Ju JH,Kim J,Noh DY,Lee T,Shin I||IUBMB life (62:41)||2010|
Tiam1-deficiency impairs mammary tumor formation in MMTV-c-neu but not in MMTV-c-myc mice.
MA5-13675 was used in western blot to study the role of tiam1 in mammary tumor formation in MMTV-c-neu and MMTV-c-myc mice
|Strumane K,Rygiel T,van der Valk M,Collard JG||Journal of cancer research and clinical oncology (135:69)||2009|
Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
MA5-13675 was used in western blot to study the tumor inhibitory mechanism of an anti-ErbB2 antibody
|Hu S,Zhu Z,Li L,Chang L,Li W,Cheng L,Teng M,Liu J||Proteins (70:938)||2008|
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
MA5-13675 was used in western blot to investigate the impact of epidermal growth factor on neuroendocrine differentiation of LNCaP cells
|Martín-Orozco RM,Almaraz-Pro C,Rodríguez-Ubreva FJ,Cortés MA,Ropero S,Colomer R,López-Ruiz P,Colás B||Neoplasia (New York, N.Y.) (9:614)||2007|
Anti-EGFR and ErbB-2 antibodies attenuate cyclooxygenase-2 expression and cooperatively inhibit survival of human colon cancer cells.
MA5-13675 was used in western blot to examine the effect of anti-EGFR and ErbB-2 antibodies on the survival of human colon cancer cells
|Half E,Sun Y,Sinicrope FA||Cancer letters (251:237)||2007|
Gene targeting of ErbB3 using a Cre-mediated unidirectional DNA inversion strategy.
MA5-13675 was used in western blot to study the efficacy of gene targeting of ErbB3 using an in vivo recombination unidirectional DNA inversion technology
|Qu S,Rinehart C,Wu HH,Wang SE,Carter B,Xin H,Kotlikoff M,Arteaga CL||Genesis (New York, N.Y. : 2000) (44:477)||2006|
Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells.
MA5-13675 was used in western blot to study the effects of vitamin D receptor agonists on androgen-dependent LNCaP human prostate cancer cell growth
|Stewart LV,Lyles B,Lin MF,Weigel NL||The Journal of steroid biochemistry and molecular biology (97:37)||2005|
A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses.
MA5-13675 was used in western blot to develop and evaluate a multi-epitope vaccine targeting HER-2
|Dakappagari NK,Pyles J,Parihar R,Carson WE,Young DC,Kaumaya PT||Journal of immunology (Baltimore, Md. : 1950) (170:4242)||2003|
Role of MHC II affinity and molecular mimicry in defining anti-HER-2/neu MAb-3 linear peptide epitope.
MA5-13675 was used in western blot to study whether it is possible to predict which peptides will evoke a humoral immune response using the human HER-2/neu breast cancer-associated antigen as a model
|Lucchese A,Stevanovic S,Sinha AA,Mittelman A,Kanduc D||Peptides (24:193)||2003|
Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome.
MA5-13675 was used in western blot to study the immune response to EC HER-2/NEU peptides not shared by the host's proteome
|Mittelman A,Lucchese A,Sinha AA,Kanduc D||International journal of cancer (98:741)||2002|
Tyrphostin AG825 triggers p38 mitogen-activated protein kinase-dependent apoptosis in androgen-independent prostate cancer cells C4 and C4-2.
MA5-13675 was used in western blot to study the role of p38 MAP kinase in the induction of apoptosis in androgen-independent prostate cancer cells by the EGFR inhibitor typhostin AG825
|Murillo H,Schmidt LJ,Tindall DJ||Cancer research (61:7408)||2001|
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
MA5-13675 was used in western blot to study the inhibition of HER2-driven signaling and growth suppression of HER2-overexpressing tumor cells by Iressa
|Moasser MM,Basso A,Averbuch SD,Rosen N||Cancer research (61:7184)||2001|
Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action.
MA5-13675 was used in immunoprecipitation to investigate the state of HER1-HER2 interaction and modification in cell lines and tumors
|DeFazio-Eli L,Strommen K,Dao-Pick T,Parry G,Goodman L,Winslow J||Breast cancer research : BCR (13:null)||2011|
Investigation of three new mouse mammary tumor cell lines as models for transforming growth factor (TGF)-beta and Neu pathway signaling studies: identification of a novel model for TGF-beta-induced epithelial-to-mesenchymal transition.
MA5-13675 was used in immunoprecipitation to study three novel mouse mammary tumor cell lines for use in TGF-beta and Neu pathway signaling studies
|Lenferink AE,Magoon J,Cantin C,O'Connor-McCourt MD||Breast cancer research : BCR (6:R514)||2004|
Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytes.
MA5-13675 was used in immunocytochemistry to study the mechanisms by which glioma cells evade the actions of cytolytic effector lymphocytes
|Hoa N,Ge L,Kuznetsov Y,McPherson A,Cornforth AN,Pham JT,Myers MP,Ahmed N,Salsman VS,Lamb LS,Bowersock JE,Hu Y,Zhou YH,Jadus MR||Journal of immunology (Baltimore, Md. : 1950) (185:4793)||2010|
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
MA5-13675 was used in immunocytochemistry to investigate the mechanism for the malignant rhabdoid tumor treatment with trastuzumab
|Katsumi Y,Kuwahara Y,Tamura S,Kikuchi K,Otabe O,Tsuchiya K,Iehara T,Kuroda H,Hosoi H,Sugimoto T||Clinical cancer research : an official journal of the American Association for Cancer Research (14:1192)||2008|
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers.
MA5-13675 was used in immunocytochemistry to characterize cell cultures and xenografts derived from patients with ovarian cancer
|Verschraegen CF,Hu W,Du Y,Mendoza J,Early J,Deavers M,Freedman RS,Bast RC,Kudelka AP,Kavanagh JJ,Giovanella BC||Clinical cancer research : an official journal of the American Association for Cancer Research (9:845)||2003|
avian erythroblastosis oncogene B 2; Avian erythroblastosis viral (v-erb-B2) oncogene homologue 2 (neuro/glioblastoma derived oncogene homolog); c-erb B2/neu protein; C-erbB-2; CD340; epidermal growth factor receptor-related protein; herstatin; human epidermal growth factor receptor 2; metas; metastatic lymph node gene 19 protein; MLN 19; MLN19; NEU; Neu oncogene; NEU proto-oncogene; neuro/glioblastoma derived oncogene homolog; neuroblastoma/glioblastoma derived oncogene homolog; NGL; p185erbB2; p185neu; proto-oncogene c-ErbB-2; proto-oncogene NEU; receptor tyrosine-protein kinase erbB-2; tyrosine kinase-type cell surface receptor HER2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2; v-erb-b2 avian erythroblastic leukemia viral oncoprotein 2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog
c-erbB2; c-neu; CD340; Erbb-2; ERBB2; HER-2; HER-2/neu; HER2; Kiaa3023; mKIAA3023; MLN 19; MLN19; NEU; NGL; TKR1